Companies/Minerva Neurosciences, Inc.

Company profile

Minerva Neurosciences, Inc.

NASDAQ: NERV · Healthcare · Biotechnology

PublicHQ Burlington, MA · MiddlesexCIK 0001598646Reports USD

#1163 of 1,418 Healthcare companies by revenue

EA Score

38D

FH 16DQ 68GM —SS 48

v0.1 · 55/100 weight · provisional

↑ filing timeliness, market scale · ↓ Piotroski F, return on assets

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$293.4M

Employees

as of 2026-09-18

Market cap

$161.2M

as of 2026-09-18

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$0$02024

Net income-$293.4M-$293.4M2025

Operating income-$15.1M-$15.1M2025

Total assets$98.0M$98.0M2025

Liabilities$233.8M$233.8M2025

Equity-$140.7M-$140.7M2025

Revenue trend

FY2018 – FY2024 · USD

FY18

FY19

$41.2M

FY20

FY21

FY22

FY23

FY24

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

What is Minerva Neurosciences, Inc.’s revenue?

Minerva Neurosciences, Inc. booked $0 in FY2024 revenue — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.

Peers · Healthcare

Zentalis Pharmaceuticals, Inc.40D Eledon Pharmaceuticals, Inc.39D Nkarta, Inc.47D Immuneering Corporation43D Spruce Biosciences, Inc.40D TuHURA Biosciences, Inc.36D

Neighbors

Middlesex →

GE Vernova Inc.$38.1B65B Thermo Fisher Scientific Inc.$44.6B86A Analog Devices, Inc.$11.0B87A The TJX Companies, Inc.$60.4B85A Boston Scientific Corporation$20.1B88A Moderna, Inc.$1.9B52D

Key facts

CEORemy Luthringer

SectorHealthcare

IndustryBiotechnology

HeadquartersBurlington, MA

ExchangeNASDAQ: NERV

Employees7

IPO date2014-07-01

Latest filings

8-K2026-08-12 10-Q2026-08-07 8-K2026-08-07 8-K2026-06-04 8-K2026-05-27 8-K2026-05-05 10-Q2026-05-05 DEF 14A2026-04-23

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.